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Abstract
In this short report we illustrate a case of extensive sodium polystyrene sulfonate (SPS) aspiration
as an immediate cause of death in a terminally ill patient. SPS is a cation exchange resin utilized to
decrease potassium levels in patients with renal failure. When administered rectally in conjunction
with sorbitol, colonic necrosis and perforation have been documented. On the other hand, oral
administration can be complicated by aspiration, especially in very ill or debilitated patients. In our
current report, histological examination of a patient who aspirated SPS shows multiple polygonal
to amorphous basophilic crystalline particles deposited intraalveolarly. The purpose of our report
is to familiarize pathologists with the histologic features of this rare iatrogenic complication of
therapy for hyperkalemia.
Findings
We report a case of a 45 year-old male patient with a his-
tory of HIV, Hepatitis B, and Hepatitis C secondary to
illicit drug use. He also suffered from end-stage renal dis-
ease with persistent hyperkalemia which was treated with
hemodialysis. The patient was admitted for a total right
hip arthroplasty as a treatment for severe osteoarthritis.
On post operative day four the patient suffered changes in
mental status, fever, and decreased saturations and was
treated for a presumptive diagnosis of pneumonia. On
post operative day nine potassium levels remained ele-
vated and the patient was administered 15 grams of SPS
solution orally. One hour later the patient developed poor
saturations, was severely hypoxemic, deteriorated, and
expired.
Post mortem gross examination revealed severe pulmo-
nary congestion (right lung 1,260 grams; left lung 1,080
grams) with focal consolidations. There was no evidence
of emboli and the airways were free of any gastric con-
tents. Additional pertinent gross findings included a
remote left ventricular infarct, cardiomegaly (680 grams),
and hepatosplenomegaly (liver 2,240 grams; spleen 430
grams).
Histological examination of all lung lobes revealed exten-
sive intraalveolar deposition of purple polygonal to amor-
phous crystals ranging in measurement from 1 to 60
micrometers (Figure 1). Additionally, there were geo-
graphic foci of bacterial bronchopneumonia and diffuse
emphysematous changes. Tissue gram stain was positive
for gram-positive cocci in chains.
Discussion
The administration of sodium polystyrene sulfonate
(SPS) is used extensively for the treatment of hyperkale-
mia, especially in patients with renal failure [1-3]. Other
uses have been reported, however [4-7]. SPS is an ion-
exchange resin that exchanges Na+ for K+ in the gastroin-
testinal tract, especially in the colon, and increases the
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fecal excretion of potassium ions. It can be administered
orally or rectally suspended in sorbitol, water, or dextrose.
Historically, reports of ischemic colitis and colonic necro-
sis after rectal administration of SPS in sorbitol solution
are abundant in the literature, but rare for the upper gas-
trointestinal tract [8-18]. Other complications such as
thrombocytopenia [19] and rectal stenosis [20] have been
reported. Administration of SPS suspended in dextrose or
water has been suggested to avoid sorbitol related compli-
cations; however, recent reports have shown sorbitol-free
SPS enemas to cause similar colonic catastrophes [21].
SPS aspiration is a potential complication of oral admin-
istration, especially in debilitated patients [22,23]. One
study reports an incidence of intestinal necrosis in 1.8%
of post operative patients [13]. The aspiration of SPS was
first described by Oi [24] in 1978 in a post term hyperka-
lemic female infant with meconium aspiration. After a
second oral administration the infant became cyanotic,
bradycardic, apneic, and expired [24]. The microscopic
appearance of the intraalveolar material was then com-
pared to a solution of 25% SPS which yielded similar his-
tological features [24]. In an animal model, Haupt et al
[25] demonstrated that the inflammatory reaction follow-
ing SPS aspiration is not solely attributed to concomitant
aspiration of gastric contents.
The purpose of this report is to document a rare, often
undiagnosed, and fulminant cause of death among
patients with renal failure under the administration of
potassium lowering agents. The particular appearance of
SPS on histological sections should highlight it as a possi-
ble cause of aspiration pneumonia. In our patient, SPS
aspiration superimposed on an already compromised
pulmonary function was the immediate cause of death.
Both methods of administration of the cation exchange
resin have been proven effective, but rectal administration
may prove beneficial in avoiding aspiration pneumonitis
in chronically ill and debilitated patients.
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A – Medium power magnification demonstrating purple  polygonal intraalveolar kayexalate crystals on a background  of emphysematous changes Figure 1
A – Medium power magnification demonstrating pur-
ple polygonal intraalveolar kayexalate crystals on a 
background of emphysematous changes. Scale bar 
1000 μm. B – High power magnification showing the SDS 
crystals in high detail measuring up to 60 μm as well as 
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